Duchenne Muscular Dystrophy Clinical Trial (DMD)
Double-blind, Randomized, Placebo-controlled Study of VECTTOR Treatment for Duchenne Muscular Dystrophy
The primary objective of this investigation is to assess the effectiveness of transcutaneous electrical nerve stimulation applied using VECTTOR to reduce the symptoms of Duchenne Muscular Dystrophy and reduce the impact of DMD upon the participants' quality of life.
The primary outcome measures will include:
- increased muscle strength,
- increased range of joint motions and
- improved sleep parameters of ASI, N3 and REM.
調査の概要
詳細な説明
Muscle Strength and Joint Range of Motion Testing - All muscle and joint testing was performed at the MedCenter Therapy clinic in Houston, Texas. JTech computerized testing system was utilized including Goniometry, Grip testing, Inclinometry, Muscle Testing and Joint Range of Motion testing occurred on Day 0, 30, 60, 90, 180, and repeated at 12 months to determine muscular strength and joint Range of Motion. JTech computerized testing system was chosen on the basis of reliability and accuracy. At each of the testing intervals, the testing was administered by the same technician with the same equipment to all of the participants. Inter-and intra-tester reliability of the JTech computerized testing system has been the subject of multiple studies. Each of which found high ICCs (>0.93) for both inter- and intra-tester reliability.
All sleep studies were performed at Sleep Diagnostics of Texas in The Woodlands, Texas. Prior to the clinical trial, all of the participants spent two nights in the sleep unit and their sleep study examinations were performed. The second night was used as the Day 0 data. Sleep, breathing, arousals and limb movements were scored manually according to guidelines set forth by the American Academy of Sleep Medicine. The sleep studies were repeated at 6 months and 1 year.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77004
- Alan Neuromedical
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participants must have Duchenne Muscular Dystrophy diagnosis as confirmed by licensed physician, wheelchair bound, & age 8 - 20 years old.
Exclusion Criteria:
- Active cancer in the area of application of the treatment, infection, skin infection, pregnancy, thrombophlebitis, pacemaker, amputation of any part of feet or hands, taking steroids. In addition, the participant may not be in any other clinical trial during the time they are in this study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:VECTTOR
nerve stimulator treatment twice daily for duration of study - 365 days
|
The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain. Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence.
他の名前:
|
プラセボコンパレーター:Device - sham
placebo treatment - no electrical stimulation treatment twice daily for duration of study, 180 days - if VECTTOR arm experiencing improvement, subjects in Device-Sham arm will be crossed over into the VECTTOR group and followed for an additional 180 days, for a total study involvement (duration) of 365 days>
|
The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain. Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Percent Change in Range of Motion From Baseline to 180 Days
時間枠:Baseline to 180 days
|
Range of Motion (ROM) testing (Wireless Tracker System) - All muscle and joint testing was performed using the JTech computerized testing system, including Goniometry, Grip Testing, Inclinometry, Muscle Testing and Joint Range of Motion.
Testing occurred at Baseline (Day 0), 30, 60, 90 and 180 days to determine changes in joint Range of Motion.
JTech computerized testing system determined the joint range of motion by radio signals from a goniometer measuring movement of the participants' joints.
44 separate tests were performed for Range of Motion for each participant at each time interval.
The results from the range of motion tests were averaged the percent change from baseline to 180 days.
Efficacy is defined as an increase in range of motion.
|
Baseline to 180 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Percent Change in Muscle Strength
時間枠:Baseline to 180 days
|
Muscle strength testing (Wireless Tracker system) - All muscle strength testing was performed using the JTech computerized testing system, including Goniometry, Grip Testing, Inclinometry, Muscle Testing and Joint Range of Motion.
Testing occurred at Baseline (Day 0), 30, 60, 90, and 180 days to determine changes in muscle strength.
JTech computerized testing system determined the muscle strength by radio signals from a strain gauge measuring strength of the participant's muscles.
44 separate tests were performed for muscle strength for each participant at each time interval.
Efficacy is defined as an increase in the strength measurement (pounds) from Baseline to 180 days.
|
Baseline to 180 days
|
Percent Change in Percent Range of Motion From Baseline to 365 Days
時間枠:Baseline to 365 days
|
Range of Motion (ROM) testing (Wireless Tracker System) - All muscle and joint testing was performed using the JTech computerized testing system, including Goniometry, Grip Testing, Inclinometry, Muscle Testing and Joint Range of Motion.
Testing occurred at Baseline (Day 0), 30, 60, 90, 180 and 365 days to determine changes in joint Range of Motion.
JTech computerized testing system determined the joint range of motion by radio signals from a goniometer measuring movement of the participants' joints.
44 separate tests were performed for Range of Motion for each participant at each time interval.
The results from the range of motion tests were averaged the percent change from baseline to 365 days.
Efficacy is defined as an increase in range of motion.
|
Baseline to 365 days
|
Percent Change in Muscle Strength
時間枠:Baseline to 365 days
|
Muscle strength testing (Wireless Tracker system) - All muscle strength testing was performed using the JTech computerized testing system, including Goniometry, Grip Testing, Inclinometry, Muscle Testing and Joint Range of Motion.
Testing occurred at Baseline (Day 0), 30, 60, 90, 180 and 365 days to determine changes in muscle strength.
JTech computerized testing system determined the muscle strength by radio signals from a strain gauge measuring strength of the participant's muscles.
44 separate tests were performed for muscle strength for each participant at each time interval.
Efficacy is defined as an increase in the strength measurement (pounds) from Baseline to 365 days.
|
Baseline to 365 days
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Percent Change in Sleep Quality Arousal Statistics Index (ASI) From Baseline to 180 Days
時間枠:Baseline to 180 days
|
Sleep / Arousal Statistics Index (ASI) description: Sleep Studies were obtained twice before beginning the study.
The second sleep study data was used as baseline.
A follow up sleep study was obtained after 6 months (180 days) of Active or Placebo VECTTOR treatment.
Sleep, breathing, arousal(s), and limb movements were scored manually according to guidelines of the American Academy of Sleep Medicine.
The efficacy of the outcome measure of ASI is demonstrated by a percent improvement between Baseline and 180 days.
The ASI is measured by the number of times sleep is interrupted per hour.
|
Baseline to 180 days
|
Sleep Arousal Statistics Index at 365 Days
時間枠:Baseline to 365 days
|
Sleep / Arousal Statistics Index (ASI) description: Sleep Studies were obtained twice before beginning the study.
The second sleep study data was used as baseline.
A follow up sleep study was obtained after 6 months (180 days) of Active or Placebo VECTTOR treatment.
Sleep, breathing, arousal(s), and limb movements were scored manually according to guidelines of the American Academy of Sleep Medicine.
The efficacy of the outcome measure of ASI is demonstrated by a decrease in the value between Baseline and 180 days.
The ASI is measured by the number of times sleep is interrupted per hour.
Lower ASI values/numbers indicate improved sleep quality.
|
Baseline to 365 days
|
協力者と研究者
捜査官
- 主任研究者:Charlotte Stelly-Seitz, MD、Pediatric Physical Medicine and Rehabilitation Houston, Texas
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- VECTTOR DMD2012
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。